Trading Statement
January 25 2008 - 5:00AM
UK Regulatory
RNS Number:5420M
Chromogenex PLC
25 January 2008
Chromogenex plc
(the 'Company')
Trading Statement
As previously reported on 9 January 2008, the Company announced that it had
received record levels of orders in the final quarter of 2007 which resulted in
the Company stating that it expected earnings for 2007 to be in line with market
expectations. Since that statement, the Company has received notification from
the Canadian Health Authority that remedial action is required on the part of
the Company and its distributor in order to satisfy the registration
requirements for the products being sold in this market. The Company is working
with the Canadian Health Authority in taking the appropriate corrective measures
and seeking the required licences for the devices. Once these measures are
resolved the Directors expect the sales in Canada to recommence.
As a result of this, the Directors feel it appropriate to defer any orders so
far received from Canada for those products until such remedial action is
complete which will have an adverse impact on the expected earnings for 2007.
Because of this the Company's results for the year ended 31 December 2007 will
be significantly below market expectations and the Directors anticipate
reporting a loss for the period. Having taken action to address these issues,
and since the deferred sales are expected to still contribute to this financial
year once the remedial action has been satisfactorily concluded, the Board
remains confident about the year ahead.
For further information contact:
Chromogenex plc 01554 755444
Allan Branch, CEO
HB Corporate 020 7510 8600
Luke Cairns/Rachel Kane
Threadneedle Communications 020 7936 9605
Graham Herring/Alex White
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTFKPKQCBKKQDB
Chromogenex (LSE:CGX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Chromogenex (LSE:CGX)
Historical Stock Chart
From Feb 2024 to Feb 2025